- Conditions
- Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
- Interventions
- bremelanotide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sexual Arousal Disorder
- Interventions
- Bremelanotide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 21 Years to 70 Years · Female only
- Timeline
- 2006 – 2007
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 17 more
- Conditions
- Kidney Disease
- Interventions
- Bremelanotide, RAAS inhibition therapy
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Chula Vista, California • La Mesa, California • Decatur, Georgia + 6 more
- Conditions
- Obesity
- Interventions
- bremelanotide, tirzepatide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Bremelanotide, Placebo
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
- Conditions
- Nausea
- Interventions
- Bremelanotide, Zofran, Placebo
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 228 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Bremelanotide, Placebo
- Drug · Other
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more
- Conditions
- Lactating Mother
- Interventions
- Vyleesi (Bremelanotide Injection)
- Drug
- Lead sponsor
- Cosette Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Doral, Florida